UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 259

Sortiert nach

Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib

Clinical pharmacology and therapeutics, 2010-02, Vol.87 (2), p.197-203

2010

Volltextzugriff (PDF)

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

Leukemia, 2013-06, Vol.27 (6), p.1254-1262

2013

Volltextzugriff (PDF)

Compensatory PI3-kinase Akt mTor activation regulates imatinib resistance development

Leukemia, 2005-10, Vol.19 (10), p.1774-1782

2005

Volltextzugriff (PDF)

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

Leukemia, 2007-11, Vol.21 (11), p.2311-2315

2007

Volltextzugriff (PDF)

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

Leukemia, 2012-07, Vol.26 (7), p.1475-1481

2012

Volltextzugriff (PDF)

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

Leukemia, 2012-05, Vol.26 (5), p.959-962

2012

Volltextzugriff (PDF)

The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR ABL

Leukemia, 2009-09, Vol.23 (9), p.1614-1621

2009

Volltextzugriff (PDF)

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

Oncogene, 2009-06, Vol.28 (22), p.2205-2218

2009

Volltextzugriff (PDF)

High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007-06, Vol.852 (1), p.208-216

2007

Volltextzugriff (PDF)

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

Leukemia, 2013-01, Vol.27 (1), p.107-112

2013

Volltextzugriff (PDF)

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Leukemia, 2017-11, Vol.31 (11), p.2523-2525

2017

Volltextzugriff (PDF)

Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR ABL

Leukemia, 2009-12, Vol.23 (12), p.2242-2247

2009

Volltextzugriff (PDF)

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

Leukemia, 2003-09, Vol.17 (9), p.1707-1712

2003

Volltextzugriff (PDF)

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies

Haematologica (Roma), 2014-01, Vol.99 (1), p.7

2014

Volltextzugriff (PDF)

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

Leukemia, 2003-12, Vol.17 (12), p.2392-2400

2003

Volltextzugriff (PDF)

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

Leukemia, 2013-08, Vol.27 (8), p.1628-1636

2013

Volltextzugriff (PDF)

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

Leukemia, 2017-12, Vol.31 (12), p.2799-2806

2017

Volltextzugriff (PDF)

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

Leukemia, 2002-12, Vol.16 (12), p.2358-2365

2002

Volltextzugriff (PDF)

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation

Leukemia, 2015-05, Vol.29 (5), p.1104-1114

2015

Volltextzugriff (PDF)

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

BMC cancer, 2016-07, Vol.16 (1), p.420-420, Article 420

2016

Volltextzugriff (PDF)

Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004-01, Vol.799 (1), p.23-36

2004

Volltextzugriff (PDF)

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors

BMC cancer, 2016-07, Vol.16 (1)

2016

Volltextzugriff (PDF)

Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry

AIDS (London), 1997-07, Vol.11 (9), p.1111-1118

1997

Volltextzugriff (PDF)

1 – 25 von 259

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(239)
Mit Volltextzugriff
(217)

Publikationsform

Artikel
(258)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(180)
Life Sciences & Biomedicine
(163)
Science & Technology
(163)
Biological And Medical Sciences
(115)
Hematology
(109)
Medical Sciences
(99)
Adult
(79)
Middle Aged
(71)
Female
(68)
Male
(66)
Oncology
(66)
Aged
(55)
Pharmacology. Drug Treatments
(49)
Hematologic And Hematopoietic Diseases
(48)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(44)
Leukemia
(41)
Imatinib Mesylate
(40)
Benzamides
(38)
Antineoplastic Agents
(33)
Adolescent
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Leukemia
(52)
Blood
(37)
Journal Of Clinical Oncology
(18)
Annals Of Hematology
(13)
Haematologica
(11)
Experimental Hematology
(8)
Leukemia Research
(6)
Aids Research And Human Retroviruses
(5)
The Journal Of Immunology
(5)
British Journal Of Haematology
(4)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

Compensatory PI3-kinase Akt mTor activation regulates imatinib resistance development

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR ABL

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR ABL

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry

Suchergebnisse filtern